2024-11-01 2025-10-31 false Capium Accounts Production 1.1 13686718 2024-11-01 2025-10-31 13686718 bus:AbridgedAccounts 2024-11-01 2025-10-31 13686718 bus:FRS102 2024-11-01 2025-10-31 13686718 bus:AuditExemptWithAccountantsReport 2024-11-01 2025-10-31 13686718 bus:SmallCompaniesRegimeForAccounts 2024-11-01 2025-10-31 13686718 bus:PrivateLimitedCompanyLtd 2024-11-01 2025-10-31 13686718 2024-11-01 2025-10-31 13686718 2025-10-31 13686718 bus:RegisteredOffice 2024-11-01 2025-10-31 13686718 core:WithinOneYear 2025-10-31 13686718 core:AfterOneYear 2025-10-31 13686718 1 2024-11-01 2025-10-31 13686718 bus:Director1 2024-11-01 2025-10-31 13686718 bus:Director1 2025-10-31 13686718 2023-11-01 13686718 bus:LeadAgentIfApplicable 2024-11-01 2025-10-31 13686718 2024-10-31 13686718 core:ComputerEquipment 2024-11-01 2025-10-31 13686718 core:ComputerEquipment 2025-10-31 13686718 core:ComputerEquipment 2024-10-31 13686718 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2025-10-31 13686718 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-10-31 13686718 core:CostValuation core:Non-currentFinancialInstruments 2025-10-31 13686718 core:CostValuation core:Non-currentFinancialInstruments 2024-10-31 13686718 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2025-10-31 13686718 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2025-10-31 13686718 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2025-10-31 13686718 core:Non-currentFinancialInstruments 2025-10-31 13686718 core:Non-currentFinancialInstruments 2024-10-31 13686718 core:ShareCapital 2025-10-31 13686718 core:RetainedEarningsAccumulatedLosses 2025-10-31 13686718 dpl:Item1 2024-11-01 13686718 dpl:Item1 2025-10-31 iso4217:GBP xbrli:shares xbrli:pure

Registered Number: 13686718
England and Wales
MASKAZ PHARMA LIMITED
Abridged Accounts
Period of accounts Start date: 01 November 2024 End date: 31 October 2025

MASKAZ PHARMA LIMITED Contents Page For the year ended 31 October 2025
Accountants' report | 1
Statement of financial position | 2
Notes to the financial statements | 3

MASKAZ PHARMA LIMITED Accountants' Report For the year ended 31 October 2025
Accountant’s report You consider that the company is exempt from an audit for the year ended 31 October 2025 . You have acknowledged, on the balance sheet, your responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These responsibilities include preparing accounts that give a true and fair view of the state of affairs of the company at the end of the financial year and of its profit or loss for the financial year. In accordance with your instructions, we have prepared the accounts which comprise the Profit and Loss Account, the Statement of Comprehensive Income, the Balance Sheet, the Statement of Changes in Equity and the related notes from the accounting records of the company and on the basis of information and explanations you have given to us. We have not carried out an audit or any other review, and consequently we do not express any opinion on these accounts. MGWM 31 October 2025 .................................................... MGWM 248 Lockwood Road Huddersfield HD1 3TG 10 April 2026 1

MASKAZ PHARMA LIMITED Statement of Financial Position As at 31 October 2025
| Notes | 2025 £
--- | --- | ---
Fixed assets |  |
Tangible fixed assets | 3 | 437
|  | 437
Current assets |  |
Debtors |  | 8,304
Cash at bank and in hand |  | 16,659
|  | 24,963
Creditors: amount falling due within one year |  | (24,417)
Net current assets |  | 546
Total assets less current liabilities |  | 983
Accruals and deferred income |  | (883)
Net assets |  | 100
Capital and reserves |  |
Called up share capital |  | 100
Profit and loss account |  | 0
Shareholders' funds |  | 100
For the year ended 31 October 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. Director's responsibilities: The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476. The director acknowledges their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts. These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. In accordance with Section 444 of the Companies Act 2006, the income statement has not been delivered to the Registrar of Companies. The members have agreed to the preparation of abridged accounts for this accounting period in accordance with section 444(2A). The financial statements were approved by the director on 10 April 2026 and were signed by:
------------------------------- ARIF KHAN Director
2

MASKAZ PHARMA LIMITED Notes to the Abridged Financial Statements For the year ended 31 October 2025
General Information MASKAZ PHARMA LIMITED is a private company, limited by shares, registered in England and Wales, registration number 13686718, registration address 69 WORDSWORTH ROAD, SMALL HEATH BIRMINGHAM, B10 0ED. The presentation currency is £ sterling.
1. | Accounting policies Significant accounting policies Statement of compliance These financial statements have been prepared in compliance with FRS 102 – The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006. Basis of preparation The financial statements have been prepared under the historical cost convention as modified by the revaluation of land and buildings and certain financial instruments measured at fair value in accordance with the accounting policies. The financial statements are prepared in sterling which is the functional currency of the company. Turnover Turnover comprises the invoiced value of goods and services supplied by the company, net of Value Added Tax and trade discounts. Taxation Taxation represents the sum of tax currently payable and deferred tax. Tax is recognised in the statement of income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. The company’s liability for current tax is calculated using the tax rates and laws that have been enacted or substantively enacted at the reporting date. Current and deferred tax assets and liabilities are not discounted Tangible fixed assets Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
Computer Equipment | 20% Reducing Balance
2. | Average number of employees Average number of employees during the year was 3.
3. | Tangible fixed assets
Cost or valuation | Computer Equipment |  | Total
| £ |  | £
At 01 November 2024 | 2,798 |  | 2,798
Additions | - |  | -
Disposals | - |  | -
At 31 October 2025 | 2,798 |  | 2,798
Depreciation
At 01 November 2024 | 1,704 |  | 1,704
Charge for year | 657 |  | 657
On disposals | - |  | -
At 31 October 2025 | 2,361 |  | 2,361
Net book values
Closing balance as at 31 October 2025 | 437 |  | 437
Opening balance as at 01 November 2024 | 1,094 |  | 1,094
3